Shannon Moore serves as a Principal Scientist at Genentech, where she plays a pivotal role in advancing the field of oncology, specifically focusing on Multiple Myeloma (MM). In her current position as the Global Development Team Biomarker Lead, Shannon is at the forefront of seven...
Shannon Moore serves as a Principal Scientist at Genentech, where she plays a pivotal role in advancing the field of oncology, specifically focusing on Multiple Myeloma (MM). In her current position as the Global Development Team Biomarker Lead, Shannon is at the forefront of seven Phase I clinical studies that evaluate innovative immunotherapy combinations. Her expertise in translational science and clinical biomarker data is instrumental in formulating biomarker-based patient stratification strategies, ensuring that the right patients receive the right therapies at the right time.
Shannon’s leadership extends beyond her technical acumen; she successfully orchestrates cross-functional teams of over 40 professionals across various business units. This collaborative approach not only enhances the scientific rationale behind clinical development decisions but also fosters strategic partnerships that are essential for navigating the complexities of drug development. Her ability to connect people and ideas is a hallmark of her career, as she actively seeks unique approaches to problem-solving and innovation in the oncology space.
Currently, Shannon is spearheading efforts to expand novel bispecific combination strategies in MM, with plans for trials that span multiple regions. Her strategic vision and communication skills enable her to effectively convey complex scientific concepts to diverse stakeholders, ensuring alignment and progress across all phases of clinical study design and execution. As she continues to drive advancements in immunotherapy, Shannon remains committed to her mission of uncovering new opportunities and forging collaborative relationships that will ultimately enhance patient outcomes in the fight against cancer.
